Janssen Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?
JANSSEN PHARMS has fifty-seven approved drugs.
There are twenty-three US patents protecting JANSSEN PHARMS drugs.
There are six hundred and four patent family members on JANSSEN PHARMS drugs in sixty-two countries and ninety supplementary protection certificates in seventeen countries.
Summary for Janssen Pharms
| International Patents: | 604 |
| US Patents: | 23 |
| Tradenames: | 56 |
| Ingredients: | 34 |
| NDAs: | 57 |
Drugs and US Patents for Janssen Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | ORTHO CYCLEN-21 | ethinyl estradiol; norgestimate | TABLET;ORAL-21 | 019653-001 | Dec 29, 1989 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Janssen Pharms | TOPAMAX | topiramate | TABLET;ORAL | 020505-002 | Dec 24, 1996 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Janssen Pharms | FLOXIN | ofloxacin | TABLET;ORAL | 019735-002 | Dec 28, 1990 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Janssen Pharms | TOPAMAX SPRINKLE | topiramate | CAPSULE;ORAL | 020844-003 | Oct 26, 1998 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Janssen Pharms | DITROPAN XL | oxybutynin chloride | TABLET, EXTENDED RELEASE;ORAL | 020897-001 | Dec 16, 1998 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Janssen Pharms | TYLOX | acetaminophen; oxycodone hydrochloride | CAPSULE;ORAL | 088790-001 | Dec 12, 1984 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Janssen Pharms | TOPAMAX | topiramate | CAPSULE;ORAL | 020844-002 | Oct 26, 1998 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Pharms | RISPERDAL | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 021444-002 | Apr 2, 2003 | 4,804,663*PED | ⤷ Subscribe |
| Janssen Pharms | LEVAQUIN | levofloxacin | TABLET;ORAL | 020634-001 | Dec 20, 1996 | 5,053,407*PED | ⤷ Subscribe |
| Janssen Pharms | RAZADYNE | galantamine hydrobromide | TABLET;ORAL | 021169-003 | Feb 28, 2001 | 6,099,863 | ⤷ Subscribe |
| Janssen Pharms | TOPAMAX | topiramate | CAPSULE;ORAL | 020844-002 | Oct 26, 1998 | 6,503,884*PED | ⤷ Subscribe |
| Janssen Pharms | TOPAMAX | topiramate | CAPSULE;ORAL | 020844-002 | Oct 26, 1998 | 4,513,006*PED | ⤷ Subscribe |
| Janssen Pharms | TOPAMAX | topiramate | TABLET;ORAL | 020505-002 | Dec 24, 1996 | 6,503,884*PED | ⤷ Subscribe |
| Janssen Pharms | RISPERDAL | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 021444-001 | Apr 2, 2003 | 4,804,663*PED | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
| ➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
| ➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
| ➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
| ➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
| ➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
| ➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
| ➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
| ➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
| ➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
| ➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
| ➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
| ➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
| ➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
| ➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
| ➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
International Patents for Janssen Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 020697 | ⤷ Subscribe |
| South Africa | 200603881 | ⤷ Subscribe |
| Iceland | 8445 | ⤷ Subscribe |
| Mexico | 2009005857 | ⤷ Subscribe |
| Japan | 1613224 | ⤷ Subscribe |
| China | 1772751 | ⤷ Subscribe |
| Japan | 2008528441 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0206283 | 98C0041 | Belgium | ⤷ Subscribe | PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606 |
| 0368388 | 07C0044 | France | ⤷ Subscribe | PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625 |
| 0206283 | C980016 | Netherlands | ⤷ Subscribe | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 |
| 0428296 | SPC/GB98/013 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923 |
| 0206283 | SPC/GB97/085 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606 |
| 1769785 | C300521 | Netherlands | ⤷ Subscribe | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 |
| 0368388 | SPC/GB07/065 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
